Monthly administration of PTH-CBD showed a longer duration of spinal BMD improvement, increased ALP levels, and less hypercalcemia or osteosarcoma risk in mice compared to weekly administration of PTH (1–34). This evidence concerns the gene PTH and osteosarcoma.